13-1837442 · New York, NY
SEE ON SCHEDULE OTHE CANCER RESEARCH INSTITUTE'S MISSION IS TO SAVE MORE LIVES BYFUELING THE DISCOVERY AND DEVELOPMENT OF POWERFUL IMMUNOTHERAPIES FORALL TYPES OF CANCER. TO ACCOMPLISH THIS, CRI FUNDS LABORATORY,TRANSLATIONAL, AND CLINICAL RESEARCH.
Total revenue
$32.3M
FY2023
Total expenses
$38.6M
FY2023
Net assets
$68M
FY2023
Operating margin
-19.4%
NPLens analysis
FY18–FY2023 · from annual filings
Financial health
C+
Derived analysis — not an official IRS designation.
Computed from FY2023 · derived analysis
FY2023 · program vs. administration vs. fundraising (Form 990, Part IX)
FY2023 · where revenue comes from (as reported)
Highest-paid officers, directors & key employees · FY2023.
JILL O'DONNELL-TORMEY PHD
CEO/DIR. OF SCIENTIFIC AFFAIRS
$602,303
ALFRED R MASSIDAS
CFO/DIR. OF HUMAN RESOURCES
$425,801
LYNNE A RAPINO
CHIEF PROGRAM OFFICER
$364,304
JAY R CAMPBELL
MANAGING DIR. OF CRI CLINICAL ACCELERATOR AND VENT
$355,403
SHARON S SLADE
CHIEF MARKETING OFFICER
$305,510
Each figure on this page traces to one of these source returns.
Health scores, efficiency ratios, peer percentiles, and outlier flags are derived analysis by NPLens — not official IRS designations. Figures are as reported on the organization's Form 990 filings. How these are computed →